Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty

Journal of Arthroplasty

Volumn 30, Issue 2, 2015, Pages 272-276

  Duncan, Christopher M ^a   Gillette, Blake P ^a   Jacob, Adam K ^a   Sierra, Rafael J ^a   Sanchez Sotelo, Joaquin ^a   Smith, Hugh M ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Hip arthroplasty; Knee arthroplasty; Mortality; Tranexamic acid; Venothromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; TRANEXAMIC ACID; WARFARIN; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANEXAMIC ACID; VENOUS THROMBOEMBOLISM;

EID: 84925042467     PISSN: 08835403     EISSN: 15328406     Source Type: Journal    
DOI: 10.1016/j.arth.2014.08.022     Document Type: Article

References (45)

1. Lozano M., Basora M., Peidro L., et al. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. Vox Sang 2008, 95(1):39.
2. Alvarez J.C., Santiveri F.X., Ramos I., et al. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion 2008, 48(3):519.
3. Molloy D.O., Archbold H.A., Ogonda L., et al. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. J Bone Joint Surg Br 2007, 89(3):306.
4. Claeys M.A., Vermeersch N., Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg 2007, 107(4):397.
5. Zufferey P., Merquiol F., Laporte S., et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology 2006, 105(5):1034.
6. Yamasaki S., Masuhara K., Fuji T. Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases. Int Orthop 2004, 28(2):69.
7. Hynes M., Calder P., Scott G. The use of tranexamic acid to reduce blood loss during total knee arthroplasty. Knee 2003, 10(4):375.
8. Husted H., Blond L., Sonne-Holm S., et al. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand 2003, 74(6):665.
9. Veien M., Sorensen J.V., Madsen F., et al. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand 2002, 46(10):1206.
10. Ekback G., Axelsson K., Ryttberg L., et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000, 91(5):1124.
11. Howes J.P., Sharma V., Cohen A.T. Tranexamic acid reduces blood loss after knee arthroplasty. J Bone Joint Surg Br 1996, 78(6):995.
12. Hiippala S., Strid L., Wennerstrand M., et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 1995, 74(5):534.
13. Slaughter T.F., Greenberg C.S. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol 1997, 56(1):32.
14. Dunn C.J., Goa K.L. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57(6):1005.
15. Lange M., Van Aken H., Westphal M. Prevention and treatment of major blood loss. N Engl J Med 2007, 357(12):1260. [author reply 1261].
16. Whiting D.R., Gillette B.P., Duncan C., et al. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res 2014, 472(1):66.
17. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):381S.
18. Fraser I.S., Porte R.J., Kouides P.A., et al. A benefit-risk review of systemic haemostatic agents: part 1: in major surgery. Drug Saf 2008, 31(3):217.
19. Ramsey E.Z., Smith K.M., Flynn J.D. Prophylaxis of perioperative blood loss. Orthopedics 2006, 29(8):689.
20. Tobias J.D. Strategies for minimizing blood loss in orthopedic surgery. Semin Hematol 2004, 41(1 Suppl 1):145.
21. Levy J.H. Novel pharmacologic approaches to reduce bleeding. Can J Anaesth 2003, 50(6 Suppl):S26.
22. Pulido L., Ghanem E., Joshi A., et al. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res 2008, 466(7):1710.
23. Gillette B.P., Maradit Kremers H., Duncan C.M., et al. Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty. J Arthroplasty 2013, 28(8 Suppl):137.
24. Mantilla C.B., Horlocker T.T., Schroeder D.R., et al. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 2002, 96(5):1140.
25. White R.H., Romano P.S., Zhou H., et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998, 158(14):1525.
26. Yamasaki S., Masuhara K., Fuji T. Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. J Bone Joint Surg Am 2005, 87(4):766.
27. Alipour M., Tabari M., Keramati M., et al. Effectiveness of oral tranexamic acid administration on blood loss after knee artroplasty: a randomized clinical trial. Transfus Apher Sci 2013, 49(3):574.
28. Berry D.J., Kessler M., Morrey B.F. Maintaining a hip registry for 25 years. Mayo Clinic experience. Clin Orthop Relat Res 1997, (344):61.
29. Jacob A.K., Mantilla C.B., Sviggum H.P., et al. Perioperative nerve injury after total hip arthroplasty: regional anesthesia risk during a 20-year cohort study. Anesthesiology 2011, 115(6):1172.
30. Jacob A.K., Mantilla C.B., Sviggum H.P., et al. Perioperative nerve injury after total knee arthroplasty: regional anesthesia risk during a 20-year cohort study. Anesthesiology 2011, 114(2):311.
31. Holtby H., Skowno J.J., Kor D.J., et al. New technologies in pediatric anesthesia. Paediatr Anaesth 2012, 22(10):952.
32. Kagoma Y.K., Crowther M.A., Douketis J., et al. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009, 123(5):687.
33. Panteli M., Papakostidis C., Dahabreh Z., et al. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee 2013, 20(5):300.
34. Tan J., Chen H., Liu Q., et al. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013, 184(2):880.
35. Munoz M., Paramo J.A. Antifibrinolytic agents in current anaesthetic practice: use of tranexamic acid in lower limb arthroplasty. Br J Anaesth 2014, 112(4):766.
36. Guijarro R., Montes J., San Roman C., et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011, 105(4):610.
37. Wu P.K., Chen C.F., Chung L.H., et al. Population-based epidemiology of postoperative venous thromboembolism in Taiwanese patients receiving hip or knee arthroplasty without pharmacological thromboprophylaxis. Thromb Res 2014, 133(5):719.
38. Shakur H., Roberts I., Bautista R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376(9734):23.
39. Bozic K.J., Katz P., Cisternas M., et al. Hospital resource utilization for primary and revision total hip arthroplasty. J Bone Joint Surg Am 2005, 87(3):570.
40. Schwarzkopf R., Chung C., Park J.J., et al. Effects of perioperative blood product use on surgical site infection following thoracic and lumbar spinal surgery. Spine (Phila Pa 1976) 2010, 35(3):340.
41. Steinitz D., Harvey E.J., Leighton R.K., et al. Is homologous blood transfusion a risk factor for infection after hip replacement?. Can J Surg 2001, 44(5):355.
42. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol 1997, 34(3 Suppl. 2):34.
43. Shander A., Hofmann A., Gombotz H., et al. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007, 21(2):271.
44. Hourlier H., Fennema P. Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial. Hip Int 2014, 24(1):63.
45. Levine B.R., Haughom B.D., Belkin M.N., et al. Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014, 29(9 Suppl):186.